Didier Jacqmin
Papers
1
Total Citations
2
H-Index
1
About
Dr. Didier Jacqmin is a distinguished urologic oncologist whose research has centered on renal cell carcinoma, particularly the role of targeted therapies in optimizing surgical outcomes. His major contributions lie in exploring neoadjuvant approaches to downstage kidney tumors, enabling less invasive, nephron-sparing surgeries. The AXIPAN phase II study, his most cited work, investigated axitinib—a potent VEGF receptor inhibitor—for reducing cT2a renal tumors to cT1 size, thereby allowing partial nephrectomy instead of radical nephrectomy. This work addresses a critical clinical need: preserving renal function to improve long-term survival. While his citation counts are modest, reflecting the specialized nature of early-phase surgical oncology trials, his impact is significant within urologic oncology, influencing treatment paradigms for organ-confined disease. Dr. Jacqmin’s research bridges medical oncology and surgical innovation, offering patients a chance for functional preservation without compromising oncologic control. His dedication to refining surgical candidacy through targeted therapy underscores a career committed to advancing personalized, function-sparing care for kidney cancer patients.
Research Focus
Key Achievements
Top Papers
- 1